Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Injectable vaccine composition

一种疫苗组合物、动物的技术，应用在疫苗、兽用疫苗、药物组合等方向，能够解决不明确等问题

Inactive Publication Date: 2016-04-27
NITTO DENKO CORP
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, from the example of the vaccine using the lipopolysaccharide (LPS) derived from Pantoea agglomerans (Pantoea agglomerans) described in this patent document 2, the lipopolysaccharide (LPS) derived from Pantoea agglomerans (Pantoea agglomerans) ) is not clear whether the effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Injectable vaccine composition
  • Injectable vaccine composition
  • Injectable vaccine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～4

[0102] (Examples 1-4, Comparative Examples 1-4)

[0103] Each administration group was manufactured with 10 parts.

[0104] A solution (445 μg / mL) containing influenza vaccine antigen (B / Wisconsin / 1 / 2010, manufactured by Osaka University Institute of Microbial Diseases) (445 μg / mL), and a solution derived from Pantoea agglomerans (Pantoea agglomerans ) solution (5 mg / mL) of lipopolysaccharide (manufactured by Innate Immunology Applied Science and Technology Co., Ltd.), was added to phosphate buffer saline (manufactured by NACALAITESQUE, INC.) to prepare a vaccine composition of 1000 μL. For example, in Example 1, 22.5 μL of a solution containing influenza vaccine antigen was added, 20 μL of a lipopolysaccharide solution derived from Pantoea agglomerans (Pantoea agglomerans) was added, and then phosphate buffer was added to make the total amount 1000 μL. Other Examples and Comparative Examples were also appropriately diluted to form a content equivalent to the dosage. In Compa...

Embodiment 5～8、 comparative example 5～7

[0111] In addition to changing the solution containing the influenza vaccine antigen from B / Wisconsin / 1 / 2010 to A / California / 07 / 2009 (H1N1, manufactured by Osaka University Microbiological Disease Research Association) (801 μg / mL), basically by The operations of Examples 1-4 and Comparative Examples 1-4 produced vaccine compositions corresponding to Table 2. For example, in Example 5, after adding 12.5 μL of the solution containing influenza vaccine antigen and 20 μL of the lipopolysaccharide solution derived from Pantoea agglomerans (Pantoea agglomerans), phosphate buffer was added to make the total amount 1000 μL.

[0112] Six mice (8-week-old female BALB / C mice, Japan SLC, Inc.) were anesthetized, and 100 μL of the prepared vaccine composition was subcutaneously administered to each mouse. One week after the administration, the mice were anesthetized again, and 100 μL of the prepared vaccine composition was subcutaneously administered to each mouse. One week after the seco...

Embodiment 9、 comparative example 8～10

[0116] A solution containing pneumococcal capsular polysaccharide (PneumovaxNP, manufactured by MSDK.K.) (1150 μg / mL) was used, and in Example 9, a lipopolysaccharide derived from Pantoea agglomerans (manufactured by Innate Immunology Applied Technology Research Co., Ltd.) was used Solution (5mg / mL), use glucopyranosyllipid (Glucopyranosyllipid) (MPLAs, InvivoGen company manufacture) in the comparative example 8, make with the dosage of each group that becomes Table 3, add phosphate buffer saline (NACALAITESQUE, Inc.), to prepare 1000 μL of vaccine composition. For example, in Example 9, after adding 8.7 μL of a solution containing pneumococcal capsular polysaccharide and 2 μL of a solution of lipopolysaccharide derived from Pantoea agglomerans (Pantoea agglomerans), phosphate buffer was added to make the total amount 1000 μL. To the mice, only the solution containing pneumococcal capsular polysaccharide was administered in Comparative Example 9, and only the phosphate buffer ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide an injectable vaccine composition that is safe and useful as a prophylactic or therapeutic agent for cancer or infectious diseases and can safely and effectively induce a systemic immune response. An injectable vaccine composition that is to be administered by injection to human or animals, characterized by comprising at least one kind of antigen and a lipopolysaccharide or a salt thereof as an immunostimulator, said lipopolysaccharide being derived from at least one kind of gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas and Enterobacter.

Description

technical field [0001] The present invention relates to an injectable vaccine composition useful as a prophylactic or therapeutic agent for cancer or infectious disease. In particular, the present invention relates to an injectable vaccine composition capable of safely and effectively inducing a systemic immune response by administering a specific lipopolysaccharide as an adjuvant together with an antigen. Background technique [0002] As the dosage form of vaccine preparations, most of the commercialized preparations are now injections. [0003] Current vaccine preparations, such as the usual influenza vaccine preparations used in Japan, do not contain adjuvants, and their effects are insufficient, and there are cases where influenza infection becomes severe in subjects who have been vaccinated with the vaccine preparations. [0004] In addition, human papillomavirus vaccines also contain monophosphoryl lipids as adjuvants. However, the sugar chain portion of the lipopoly...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/39A61P37/04A61K39/145A61P31/16
CPCA61K39/00A61K2039/55572A61K39/39A61P31/16A61P37/04A61P43/00A61K39/0011A61K9/0019A61K39/145A61K2039/552
Inventor 松下恭平深坂昌弘冈崎有道清远英司大久保胜之浅利大介堀光彦
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com